The adjacent insulin-like growth factor 2 (IGF2) and H19 genes are imprinted in most normal human tissues, but imprinting is often lost in tumors. The mechanisms involved in maintenance of imprinting (MOI) and loss of imprinting (LOI) are unresolved. We show here that osteosarcoma (OS) tumors with IGF2/H19 MOI exhibit allele-specific differential methylation of a CTCF-binding site upstream of H19. LOI of IGF2 or H19 in OS occurs in a mutually exclusive manner, and occurs with monoallelic expression of the other gene. Bisulfite sequencing reveals IGF2 LOI occurs with biallelic CpG methylation of the CTCF-binding site, while H19 LOI occurs with biallelic hypomethylation of this site. Our data demonstrate that IGF2 LOI and H19 LOI are accompanied by reciprocal methylation changes at a critical CTCF-binding site. We propose a model in which incomplete gain or loss of methylation at this CTCF-binding site during tumorigenesis explains the complex and often conflicting expression patterns of IGF2 and H19 in tumors.
INTRODUCTION
Genomic imprinting is the preferential silencing of one parental allele due to epigenetic modifications. Insulin-like growth factor II (IGF2), which codes for a potent mitogen (1) , and H19, a putative tumor suppressor (2) , are two imprinted genes located adjacent to each other at chromosome 11p15.5 in humans. In most tissues IGF2 is maternally imprinted (3) and H19 is paternally imprinted (4) . Loss of IGF2 and/or H19 imprinting commonly occurs in cancer, and may be involved in malignant transformation (5) (6) (7) .
The mechanisms responsible for maintenance of imprinting (MOI) and loss of imprinting (LOI) are unresolved. One potential mechanism involves differentially methylated regions (DMRs) which act as epigenetic modifiers of allelic expression by recruiting proteins that specifically bind to methylated or unmethylated DNA.
DMRs have been proposed to participate in the imprinting control of human IGF2 and H19. Within the IGF2 gene, Sullivan et al. (8) located a region spanning exons 2 and 3 which is differentially methylated, and is homologous to dmr 0 in the mouse insulin-like growth factor 2 (Igf2) gene. Loss of maternal-allele specific methylation in this region correlated with IGF2 LOI in Wilms tumors (8) . Vu et al. (9) found no similar differentially methylated patterns around IGF2 exon 5 or 8.
The most notable DMR associated with IGF2 is in the region upstream of H19. There are four specific binding sites for the zinc finger protein CTCF (CCCTC-binding factor) in this region of mouse Igf2 (10-13). CTCF binds the unmethylated maternal allele and acts as an insulator between Igf2 and downstream enhancers, thereby suppressing Igf2 transcription. Methylation of the paternal allele prevents CTCF binding, thereby precluding the establishment of the insulator and allowing Igf2 transcription.
In humans, the DMR upstream of H19 contains seven CTCFbinding sites (11) . This area is differentially methylated in most normal human tissues, with the paternal allele being methylated and the maternal allele being unmethylated (9, 14, 15) . Only the sixth of the seven CTCF-binding sites has been demonstrated to have allele-specific differential methylation (16) , and the loss of differential methylation at this site correlates with LOI in Wilms tumors (17) , bladder cancer (16) , and colon cancer (18, 19) . Hypermethylation of the normally unmethylated allele was found in Wilms tumors with IGF2 LOI (17) , while hypomethylation of the normally methylated allele was found in bladder cancers with H19 LOI (16) . One group has found moderate hypermethylation in colon cancer with IGF2 LOI (18) , although another claims hypomethylation is more prominent (19) .
A paralogue of CTCF, known as BORIS (brother of the regulator of imprinted sites) has recently been cloned. CTCF and BORIS contain the same zinc finger domain, and thus may possess a similar DNA-binding potential (20) . As the onset of BORIS expression correlates with genome-wide demethylation during male germ-line development, BORIS has been proposed to be involved in the removal of methylation marks (20) . BORIS expression has been suggested in some tumors (21) , but whether BORIS expression in tumors results in impaired DNA methylation is unknown.
Osteosarcoma (OS) is the most common primary bone tumor. We screened 72 osteosarcoma tumors from 62 patients for informative polymorphisms of IGF2 and H19, analyzed the expression of IGF2 and H19 alleles, and determined the methylation status of critical DMRs. Here we report IGF2/H19 LOI in OS. We show that BORIS is expressed in some OS tumors, and how BORIS expression may affect CpG methylation in this tumor. We demonstrate how CpG methylation of a critical CTCF-binding site may affect IGF2/H19 imprinting and we propose a model in which incomplete gain or loss of CpG methylation at this site explains the complex expression of IGF2 and H19 in tumors.
RESULTS

IGF2 and H19 genotypes in OS
A schematic of three IGF2 exon 9 polymorphisms and two H19 exon 5 polymorphisms evaluated in this study is shown in Figure 1 . The genotypes at these polymorphisms were determined by PCR for 72 OS tumor samples from 62 patients, to identify samples that were informative for IGF2 and H19. Results of OS genotyping can be found in Table 1 . Overall 28 patients were informative for IGF2 and 34 were informative for H19. Seventeen patients were informative for both IGF2 and H19. When more than one tumor sample was obtained from a single patient, these samples always displayed an identical genotype.
Allelic expression of IGF2 and H19 in OS
Samples that were heterozygous at one or more polymorphisms were analyzed for IGF2 and H19 allelic expression by reverse transcription PCR (RT-PCR). The results of allelic expression in OS can be found in Table 1 . Overall, seven of 28 patients informative for IGF2 demonstrated loss of imprinting (LOI) of IGF2. Seven of 34 patients informative for H19 demonstrated LOI of H19. Of the 17 patients informative for both genes, IGF2 LOI and H19 LOI were mutually exclusive. No patient lost imprinting for both genes, even though eight patients with LOI for one gene were informative for the other (Table 2 , IGF2 LOI patients nos 1, 3, 4 and 6 and H19 LOI patients nos 2, 3, 4 and 7). When more than one tumor sample was obtained from a single patient, these samples displayed identical allelic expression. Representative samples of OS genotypes and allelic expression are shown in Figure 2 .
IGF2 promoter usage in OS
IGF2 may be transcribed from four alternate promoters (P1-P4), of which P3 and P4 are predominant in most tissues (22) . While P2, P3, and P4 are maternally imprinted, P1 is normally biallelically expressed (23, 24) . Thus, biallelic expression of IGF2 may result from either LOI of promoters P2-P4, or from transcription from P1. To show that biallelic IGF2 expression in OS tumors was due to LOI, and not from P1 transcription, we performed multiplex PCR. Multiplex PCR was performed with 5 0 primers specific for each of the four IGF2 promoters, and with a common labeled 3 0 primer (Fig. 3A) . Products from this multiplex PCR have been shown to reflect the relative abundance of the promoter-specific derived transcripts (25) . Of 24 OS tumors examined, expression was predominantly from P3 and P4, and extremely low, if any, expression was seen from P1. Typical examples of IGF2 promoter usage from OS tumors are shown in Figure 3B .
Differentially methylated regions in OS
The methylation status of potential DMRs was determined by cloning and sequencing bisulfite treated DNA. The region upstream of H19 was examined with two pairs of PCR primers. The H19-5962BT/H19-6413BT primer pair amplifies a region from 2374 to 1923 bp upstream of the H19 transcription start site, which contains the sixth of seven CTCF-binding sites upstream of H19 (Fig. 4A) (11) . This region has been shown to be differentially methylated in normal human tissues, with one allele methylated and the other unmethylated (9) . For most OS tumors, two singlenucleotide polymorphisms (SNPs) in this region allowed categorization of clones into groups based on allele of origin. In tumors with MOI of both IGF2 and H19, one allele was nearly entirely methylated in this region, while the other was nearly entirely unmethylated. As compared with samples with MOI, tumors with IGF2 LOI had striking methylation of the normally unmethylated allele, whereas tumors with H19 LOI had variable amounts of demethylation of the normally methylated allele. Demethylation in H19 LOI was most pronounced within the CTCF-binding site.
The H19-7574BT/H19-7959BT primer pair amplifies a region from 762 to 377 bp upstream of H19 near the H19 promoter (Fig. 4B) . Two SNPs were also available in this region to categorize clones by allele of origin. Tumors with MOI or IGF2 LOI showed similar methylation patterns in this region to patterns found in the other H19 upstream region (MOI tumors contained one methylated and one unmethylated allele, while tumors with IGF2 LOI had methylation of both alleles). However, unlike the previous region, H19 LOI tumors had one methylated and one unmethylated allele.
One previous report used restriction enzyme digestion and Southern blotting to describe differential methylation of a region spanning exons 2 and 3 of IGF2 in Wilms tumors (8) .
We designed two sets PCR primers for bisulfite sequencing of this region (Fig. 4C) . One SNP polymorphism was found to categorize cloned segments by allele of origin. Bisulfite sequencing revealed that methylation of this region was not uniform in OS. No predominantly methylated or unmethylated alleles could be seen.
We used MR-PCR (methylation restriction PCR), a simplified COBRA (combined bisulfite restriction analysis) method, to verify and expand the findings of bisulfite cloning and sequencing. In the H19 upstream region, the 452 bp PCR fragment produced by the H19-5962BT/H19-6413BT primer pair would contain BstUI sites (CGCG) if CpG dinucleotides were methylated before bisulfite treatment ( Fig. 5A ; these 3 CpG sites correspond to CpG 6190, 6192 and 6194 in Fig. 4A ). MR-PCR shows that, at this CTCF-binding site, eight tumors with IGF2/H19 MOI contain both methylated and unmethylated CpG sequences. The majority of sequences in eight H19 LOI tumors were unmethylated. Restriction digestion was complete in eight IGF2 LOI tumors, representing completely methylated sequences. These results agree with bisulfite sequencing and expand the methylation analysis to a total of 24 tumors.
In the H19 promoter region, the 386 bp fragment produced by the H19-7574BT/H19-7959BT primer pair would contain a unique HpyCH4 IV site (ACGT) if the CpG at 7898 was originally methylated (Fig. 5B , compare with Fig. 4B ). HpyCH4 IV digestion shows that tumors with MOI contained both methylated and unmethylated CpG dinucleotides at this site. Most H19 LOI tumors likewise contained both methylated and unmethylated CpG dinucleotides. IGF2 LOI tumors were entirely methylated. Of note, two H19 LOI tumors from the same patient (OS158 and OS178) produced restriction fragments, suggesting that they were entirely unmethylated at this site, and this corresponds with bisulfite sequencing of OS158.
In the IGF2 exon 2/3 region, the 342 bp fragment produced by the IGF2-65759BT/IGF2-65418BT primer pair would contain a unique Taq I site (TCGA) if the CpG at 65 608 was originally 4C ). In contrast to the upstream H19 region and the H19 promoter region, in this region products representing both methylated and unmethylated CpG dinucleotides were seen in all tumors regardless of imprinting status. This confirms the heterogeneity of methylation seen in this region by bisulfite sequencing (in Fig. 4C ).
CTCF and BORIS expression in MOI and LOI
Previously, CTCF expression has been found to be nearly ubiquitous while BORIS has been found only in the testis. In OS, CTCF was ubiquitously expressed (Fig. 6 ). BORIS expression was observed after RT-PCR in nine of 24 OS 
DISCUSSION
IGF2 and/or H19 LOI commonly occurs in cancers, and may be involved in malignant transformation (5-7). IGF2 LOI, leading to biallelic production of a potent growth factor, may provide augmented growth promoting signals to a tumor. IGF2 appears to be important for OS growth, as suppression of IGF2 in OS cell lines leads to growth inhibition (26) . The mechanism by which H19 LOI may promote tumorigenesis is more difficult to explain, but H19 LOI may be a marker of more widespread epigenetic dysregulation.
Our understanding of the mechanisms underlying maintenance and loss of imprinting is incomplete. In the mouse, the H19 DMR is required for both H19 and Igf2 imprinting (27) . A current model suggests that the maternal unmethylated H19 DMR allows CTCF binding, establishing an insulator between Igf2 and downstream enhancers, which prevents Igf2 transcription and supports H19 transcription. On the methylated paternal DMR, CTCF binding is prevented, allowing for Igf2 transcription, while H19 is silenced (10, 11) . This model would predict that if the DMRs of both alleles were methylated, then Igf2 would be biallelically expressed and H19 would be silenced. Likewise, this model would predict that if the DMRs of both alleles were unmethylated, then H19 would be biallelically expressed and Igf2 would be silenced. Indeed, this predicted reciprocal pattern of gene expression was observed both in normal human development (28) and in Wilms tumors (29) (30) (31) , where IGF2 LOI was found with biallelic DMR methylation and suppression of H19 expression. In this study of osteosarcoma, IGF2 LOI and H19 LOI Table 2 . PCR primers used in this study. PCR primers are named for the gene they target and the position of the 5 0 base as documented in Genebank (accession number AF087017 for all H19 primers, X07868 for IGF2 exon 9 genotyping, AC006408 for IGF2 promoter usage and IGF2 exon 2/3 cloning, NM006565 for CTCF, and AF336042 for BORIS). Primers are labeled BT when they were designed to anneal to DNA that has been bisulfite treated. Primers for IGF2 promoter usage analysis are complementary to AC006408 sequence. '#' is the primer number used to catalog primers in our laboratory. Optimal annealing temperatures were determined by PCR on a gradient thermal cycler occurred in a mutually exclusive manner, however biallelic expression of IGF2 or H19 was still accompanied by monoallelic expression of the other gene. We used bisulfite sequencing and MR-PCR to evaluate the role of potential DMRs on IGF2 and H19 imprinting. Our findings are consistent with previous reports that in tissues with IGF2/H19 MOI, the paternal allele is methylated and the maternal allele is unmethylated at both the H19 promoter region and the sixth of seven CTCF-binding sites upstream of H19 (9, 14, 15) . In contrast to tissues with MOI, in tumors with LOI of IGF2 or H19 we found a striking loss of allele-specific methylation in these regions. Both bisulfite sequencing and MR-PCR show that hypermethylation of both regions accompanies IGF2 LOI, while hypomethylation of the CTCF-binding site accompanies H19 LOI. Thus, the switching of the methylation status at a critical CTCF-binding site can potentially explain the mutually exclusive pattern of IGF2 or H19 LOI in OS. It is interesting that the methylation status of the H19 promoter does not always correlate with H19 expression, whereas the methylation status of the CTCFbinding site does.
As the onset of BORIS expression in spermatocytes correlates with genome-wide demethylation during male germ-line development, it has been hypothesized that BORIS may act to remove methylation marks (20) . Aberrant expression of BORIS has been suggested in different tumors (21) , but the effect of BORIS expression on DNA methylation in tumors is unknown. We show here that BORIS is expressed in OS. The 'DNA' column shows the results of genotyping for the three IGF2 and two H19 polymorphisms studied. The 'cDNA' column shows the results of allelic expression analysis by RT-PCR. The '-RT' column shows controls for allelic expression analysis lacking the reverse transcription step, to verify products are derived from cDNA and not genomic DNA. As the primers for the H19 Alu I polymorphism cross an intron, products from cDNA are smaller than those from genomic DNA, and a '-RT' control was therefore not needed.
BORIS expression was found predominately among tumors with biallelic hypomethylation of the critical CTCF-binding site, consistent with the idea that BORIS may be involved in removal of methylation marks.
A model of how methylation switching may affect IGF2/H19 imprinting is described in Figure 7 . We propose that both gain-of-methylation and loss-of-methylation can occur within one tumor type, such as OS. Gain-of-methylation, the methylation of the normally unmethylated maternal allele, accompanies IGF2 LOI. Loss-of-methylation, the demethylation of the normally methylated paternal allele, accompanies H19 LOI. If gain or loss of methylation is not complete, a 'leaky' CTCF-induced insulator can result, which explains the expression of both IGF2 and H19 from the same parental allele. Therefore, biallelic expression of IGF2 (IGF2 LOI) can occur with monoallelic expression of H19 (and vice versa), as seen in this study, as well as in cervical (32) , ovarian (33) , and head and neck (34) carcinomas. If gain or loss of methylation in this region is complete, then biallelic expression of one gene may occur with silencing of the other. This pattern of methylation and gene expression frequently occurs in Wilms tumors (29) (30) (31) . Our model also allows for the occurrence of LOI of both IGF2 and H19, which has been observed in testicular germ cell tumors (35) and rarely in Wilms' tumors (29) . If gain-of-methylation of the maternal allele occurs concurrently with loss-of-methylation of the paternal allele in a population of tumor cells, then both IGF2 and H19 would be expressed biallelically. Thus, the complex and often conflicting expression patterns of IGF2 and H19 in tumors may be explained by methylation switching of a CTCF-binding region.
There are other proposed models for IGF2 LOI. In the mouse, a silencer element has been demonstrated within the Igf2 gene (36, 37) , and a tissue-specific Igf2 enhancer has been located 32 kb upstream of H19 (38) . To date, neither of these elements has been observed in humans. In Wilms' tumors, Sullivan et al. In summary, the mutually exclusive pattern of IGF2 LOI and H19 LOI in OS can potentially be explained by CpG methylation switching of a CTCF-binding site. Biallelic methylation of this critical CTCF-binding site upstream of H19 accompanies IGF2 LOI, while biallelic hypomethylation of this region accompanies H19 LOI. The demethylation associated with H19 LOI co-occurred with BORIS expression, expanding the putative role of BORIS as a remover of methylation marks in the male germline, to a similar role in cancer.
MATERIALS AND METHODS
Tumor samples and clinical data
Tumor samples were obtained from patients undergoing surgery at Memorial Sloan-Kettering Cancer Center after obtaining written informed consent under a protocol approved by The Memorial Hospital Institutional Review Board. Tissue obtained at the time of surgery was confirmed by pathologic examination and samples were flash frozen and stored at À80 C until used in molecular studies.
Nucleic acid collection from tissues
Genomic DNA was collected from tissues using a solution of 4 M guanidinium thiocyanate, 25 nM sodium citrate, 1% 2-mercaptoethanol, and 0.5% Sarkosyl as described previously (39) . The homogenate was extracted with phenol/chloroform and then precipitated with 2-propanol. The DNA pellet was washed with ethanol and dissolved in distilled water. RNA was collected from tissue using Tri-reagent (Sigma, St Louis, MO, USA).
Genotyping of IGF2 and H19 polymorphisms
Genotypes of 72 OS tissues for three potential IGF2 polymorphisms and two potential H19 polymorphisms were determined by PCR of genomic DNA as diagrammed in Figure 1 . Each PCR was performed in 6 ml volume under liquid wax. Reactions contained 200 ng of DNA, 0.1 mM appropriate Figure 4 continued.
primers, 50 mM deoxynucleoside triphosphate, and 0.2 units Klen Taq I (Ab Peptides, St Louis, MO, USA). One primer from each pair was end-labeled with g-[ 32 P]ATP. PCR conditions were 95 C for 90 s, followed by 29 cycles of 95 C for 25 s and optimal annealing temperature for 1 min, and finally 72 C for 10 min. Optimal annealing temperatures for each primer pair was determined by PCR on a gradient thermal cycler, and are listed in Table 2 .
Determination of three genotype polymorphisms required restriction enzyme digestion (Apa I, Alu I or Rsa I). For these samples, non-labeled primers were used until the last PCR cycle, when one [ 32 P] labeled primer was added. Adding labeled primer during the last PCR cycle prevents formation of labeled heteroduplexes (40) , and thus reduces errors in genotyping due to the failure of restriction enzymes to digest heteroduplexes. One microliter of PCR products was mixed with two units of appropriate enzyme (Invitrogen, Carlsbad, CA, USA) in a total volume of 20 ml, and digested at 32 C (Apa I) or 37 C (Alu I and Rsa I) for 6 h.
Products were electrophoresed on 5% polyacrylamide-urea gel and visualized by a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA).
Expression of IGF2 and H19 alleles
Samples that were heterozygous at IGF2 and/or H19 polymorphisms were analyzed for allelic expression by RT-PCR. RNA samples were treated with DNase I (Invitrogen) in the presence of RNase inhibitor (Invitrogen) to eliminate contaminating genomic DNA. Total RNA (0.4 mg), random hexamer and M-MLV reverse transcriptase (Invitrogen) were used for cDNA production. cDNA samples were PCRamplified with primers and conditions used for genotyping, but for only 27 cycles. For primer pairs that did not cross intron/ exon boundaries, a control PCR was performed without a reverse-transcription step, to verify that products were derived from cDNA and not genomic DNA. Products were electrophoresed on 5% polyacrylamide-urea gel and visualized by a Figure 5 . Restriction enzyme analysis of individual CpG dinucleotides. The schematics on the left show the location of the CpG dinucleotides analyzed, and the predicted products based on whether the original CpG dinucleotides were methylated or unmethylated. On the gels, from left to right, are a base pair marker, a fully uncut control, a fully cut control, and products from eight MOI, eight LOI H19 and eight LOI IGF2 tumors. The controls were PCR amplified from non-bisulfite treated genomic DNA with primers designed to produce the same size products as the BT primers amplify from bisulfite treated DNA. Since these controls came from non-bisulfite treated DNA, their sequence is unchanged, and they are able to be fully restriction enzyme digested. PhosphorImager. The threshold for scoring a sample as LOI was a ratio of less than 5:1 between the more abundant and less abundant alleles. In general, samples with LOI demonstrated a ratio of 1:1 to 2:1 between expressed alleles.
IGF2 promoter usage analysis cDNA samples were PCR amplified with four promoterspecific 5 0 primers and a common 3 0 primer end-labeled with g-32 P ATP (see Table 2 ). The four 5 0 primers compete for the common 3 0 primer. Products have been shown to reflect the relative abundance of the promoter-specific derived transcripts (25) . PCR conditions were the same as for genotyping.
Bisulfite treatment of genomic DNA
Bisulfite treatment of genomic DNA efficiently converts unmethylated cytosines to uracil, while 5-methylcytosine remains unchanged (41) . Two micrograms of genomic DNA were denatured in 20 ml 0.3 M NaOH for 20 min at 37 C, and then placed on ice. A 220 ml aliquot of 3.5 M sodium bisulfite containing 1 mM hydroquinone was added, and the solution was covered with liquid wax. The solution was incubated at 0 C for 12 h, then 50 C for 8 h. Resulting bisulfite treated DNA was purified using QIAEX II Extraction Kit (Qiagen, Valencia, CA, USA) and Centri-Spin20 Columns (Princeton Separations, Adelphia, NJ, USA). From 50 ml final volume in water, 1 ml was used for each subsequent analysis.
Cloning and sequencing of bisulfite-treated DNA
To determine the methylation status of cytosines in genomic DNA, DNA was bisulfite-treated, amplified by PCR, cloned and sequenced. One microliter of bisulfite treated DNA was PCRamplified with appropriate primers in a total volume of 3 ml covered with liquid wax. One primer from each pair was endlabeled with g-[
32 P]ATP. PCR conditions were 95 C for 90 s, followed by 30 cycles of 95 C for 25 s, optimal annealing temperature for 45 s, and 70 C for 45 s, and finally 70 C for 10 min. PCR products were resolved on 5% acrylamide gels. Small pieces of gel containing the desired product were cut out and eluted in 100 ml water for 20 min at 90 C. One microliter of this elution was subjected to a second round of PCR with similar conditions except with non-labeled primers and only 16 cycles. One microliter samples of the second amplification were resolved on 1% agarose gels with ethidium bromide to verify products were of the anticipated size. Successful PCR products were then cloned into the pCR2.1-TOPO vector (Invitrogen), transformed into TOP10 One Shot E.coli (Invitrogen), and plasmid DNA was collected by QIAprep Spin Mini-prep kit (Qiagen, Valencia, CA, USA). Automated sequencing of DNA was performed using Big-Dye (PerkinElmer, Wellesley, MA, USA).
Restriction enzyme analysis of bisulfite-treated DNA
The methylation status of individual cytosines can be assessed by bisulfite treatment of DNA, PCR and digestion with a restriction enzyme specific for the unchanged DNA sequence. These enzymes will only cut bisulfite-treated DNA if the cytosines being evaluated are methylated, and thus unchanged by bisulfite treatment. This method has been referred to as MR-PCR (42), and is a simplified version of COBRA (combined bisulfite restriction analysis) (43) .
Bisulfite-treated DNA was PCR amplified for 30 cycles and then eluted as described in the cloning section above. One microliter of elution was amplified in a second round of PCR with similar conditions, but for only 16 cycles. Three microliters of products from this second round of PCR were digested with 10 units of appropriate restriction enzyme (NEBL, Beverly, MA, USA) in a total volume of 40 ml for 6 h (37 C for HpyCH4 IV, 60 C for BstU I, and 65 C for Taq I). Products were electrophoresed on 5% polyacrylamide-urea gel and visualized by a PhosphorImager.
Fully cut and uncut controls were produced by PCR amplification of non-bisulfite-treated DNA. Primers were designed to anneal to genomic DNA and amplify products of the same size as those produced from bisulfite-treated DNA with BT primers. PCR conditions were the same as for genotyping. Restriction enzyme digestion conditions were the same as above.
RT-PCR of CTCF and BORIS
cDNA samples were PCR amplified with gene specific primers (see Table 2 ), which crossed intron/exon boundaries in order to verify that PCR products were derived from cDNA and not from genomic DNA. PCR conditions for CTCF amplification were 95 C for 90 s, followed by 30 cycles of 95 C for 25 s, 65 C for 45 s, and 72 C for 45 s, and finally 72 C for 10 min. PCR conditions for BORIS were 95 C for 90 s, followed by 36 cycles of 95 C for 25 s, 62 C for 45 s, and 72 C for 45 s, and finally 72 C for 10 min. (10, 11) , the maternal DMR is unmethylated, allowing CTCF binding and the establishment of an insulator which promotes H19 transcription. The paternal DMR is methylated, preventing insulator function and promoting IGF2 transcription. In LOI IGF2 tumors: there is a gain-of-methylation of the normally unmethylated maternal DMR, establishing a 'leaky' insulator, and allowing both IGF2 and H19 to be expressed from the maternal allele. In LOI H19 tumors: there is a loss-ofmethylation of the normally methylated paternal sixth CTCF-binding site, establishing a 'leaky' insulator, and allowing both IGF2 and H19 to be expressed from the paternal allele. An interesting possibility is the role of BORIS in the removal of methylation marks from the paternal CTCF-binding site, which accompanies H19 LOI.
